BTK and neoplasm: As venetoclax is increasingly used in combination, many regimens are designed with a lead-in using anti-CD20 monoclonal antibodies or Bruton tyrosine kinase inhibitors (BTKis) which may reduce tumor bulk, reclassify the patient’s TLS risk and facilitate less intensive monitoring procedures [28, 29].